US 12,239,993 B2
Devices and methods for antibiotic susceptibility testing
David Swenson, Santa Clara, CA (US); Phoebe Cao, Sunol, CA (US); Gary Schoolnik, Washington, DC (US); Bryan D. Knysh, Santa Clara, CA (US); and Teresa M. Abraham, San Jose, CA (US)
Assigned to Visby Medical, Inc., San Jose, CA (US)
Appl. No. 17/273,100
Filed by Visby Medical, Inc., San Jose, CA (US)
PCT Filed Sep. 3, 2019, PCT No. PCT/US2019/049385
§ 371(c)(1), (2) Date Mar. 3, 2021,
PCT Pub. No. WO2020/051156, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/820,359, filed on Mar. 19, 2019.
Claims priority of provisional application 62/726,379, filed on Sep. 3, 2018.
Prior Publication US 2021/0299669 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. B01L 7/00 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/689 (2018.01)
CPC B01L 7/525 (2013.01) [C12Q 1/6827 (2013.01); C12Q 1/689 (2013.01); B01L 2200/10 (2013.01); B01L 2200/16 (2013.01); B01L 2400/0478 (2013.01); B01L 2400/0644 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] 22 Claims
 
1. A molecular diagnostic device, comprising:
a sample preparation module configured to receive a biological sample, wherein the biological sample comprises a polynucleotide;
a reagent module containing a primer set targeting a single nucleotide polymorphism (SNP) locus in the polynucleotide;
an amplification module including a reaction volume and a heater, the reaction volume configured to receive the biological sample and an amplification solution comprising the primer set, the heater configured to convey thermal energy into the reaction volume to amplify the polynucleotide to produce an output containing a target amplicon comprising the SNP locus; and
a detection module configured to receive the target amplicon, the detection module including a probe designed to bind to the SNP locus of the target amplicon if the SNP locus comprises a target allele, while minimizing binding to the SNP locus of the target amplicon if the SNP locus comprises an alternative allele,
wherein the target allele is a drug-resistance allele, and the molecular diagnostic device specifically detects the drug-resistance allele in the biological sample.